The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier

Table 3

Tyrosine hydroxylase (TH) in brain and apomorphine-induced contralateral rotation after intravenous injection of gene therapy with TH expression plasmids.

Treatment (group)	Days after Rx	Apomorphine revolutions before Rx	Apomorphine revolutions after Rx	Striatal TH (pmol/h/mgp)
Saline	3	324 ± 69*	401 ± 72	162 ± 36
	6	232 ± 43	342 ± 62	288 ± 42
	10	228 ± 23	331 ± 55	120 ± 18
Clone 877	3	196 ± 24	56 ± 20^b	4286 ± 918^b
	6	231 ± 47	230 ± 55	1015 ± 213^a
	10	219 ± 35	256 ± 27	335 ± 79^a
prgTH2	3	251 ± 38	123 ± 31^b	1343 ± 176^b,c
	6	295 ± 55	119 ± 34^a	1535 ± 324^b
	10	344 ± 27	443 ± 70^c	884 ± 7^b,d
prgTH3	3	317 ± 23	234 ± 38^d	167 ± 35^d
	6	197 ± 11	127 ± 11^a	545 ± 117^a
	10	202 ± 31	111 ± 9^b,d	985 ± 101^b,d
prgTH4	3	211 ± 28	100 ± 9^b	1219 ± 137^b,c
	6	234 ± 37	113 ± 20^b	1621 ± 196^b
	10	3 ± 64	249 ± 64	500 ± 86^b
None	NA	0	0	5068 ± 168

Rx: single IV injection of TfRMAb-targeted THLs encapsulating the respective TH expression plasmid. *Mean ± S.E. (𝑛=3–6 rats per point). Statistically significant differences were determined by Student’s t-test.
Clone 877 is the TH expression plasmid driven by the SV40 promoter. For details in the engineering of TH genomic vectors, clones prgTH2–TH4, please see Figure 5.
Difference with saline: 𝑃<0.05^a; 𝑃<0.005^b.
Difference with clone 877: 𝑃<0.05^c; 𝑃<0.005^d.
NA: not applicable.
From [48].